The MHRA has approved orforglipron (Foundayo), an oral GLP-1 receptor agonist tablet, ahead of regulatory decisions in the EU and US. The approval addresses a critical manufacturing constraint that has limited supply of injectable GLP-1s, but NHS access remains contingent on a separate NICE cost-effectiveness review.
Key Points
- Oral formulation eliminates injectable manufacturing bottlenecks constraining supply
- MHRA approval is regulatory first; NHS access depends on pending NICE decision
- Dosing escalates across six-month protocol from 0.8 mg to 17.2 mg daily
Longevity Analysis
The shift from injectable to oral delivery addresses a structural supply problem that has constrained access to a pharmacological tool demonstrably affecting weight regulation and glucose metabolism. Manufacturing capacity has been a primary barrier to reaching patients who could benefit; a small-molecule tablet formulation manufactured through standard processes rather than complex peptide synthesis removes that friction. Regulatory approval does not guarantee patient access—the gap between authorization and NHS funding is substantial—but it establishes that the category's supply constraints are not inevitable. For weight management and metabolic control at population scale, this distinction between what regulators permit and what health systems fund becomes the next meaningful bottleneck.
Original published by Longevity.Technology, by Kyle Umipig.